EGFR 測試市場：市場規模（按細分市場）、份額、監管、報銷、預測（~2033 年）

在全球範圍內，肺癌是男性第二常見癌症，女性第三大常見癌症。 根據二手資料顯示，2018年全球報告了約200萬名新發肺癌病例。 吸菸是所有年齡層肺癌的主要危險因素，全世界約 80% 的男性肺癌病例和 45% 的女性肺癌病例可歸因於吸菸。

EGFR是受體酪胺酸激□家族的成員，是調節細胞增生、侵襲、轉移、血管生成和抑制細胞凋亡的關鍵因子。 EGFR 是 NSCLC 中最常檢測的生物標記之一。

腺癌中發現的大多數 EGFR 突變位於酪胺酸激□結構域。 最常見的突變是外顯子 19 中的框內缺失（約 45%）和外顯子 21 中的點突變 (L858R)，這兩種突變合計佔所描述突變的 85% 以上。 這些突變與 NSCLC 患者對 EGFR 治療（例如酪胺酸激□抑制劑 (TKI) 吉非替尼、厄洛替尼、阿法替尼和埃克替尼）的反應密切相關。

本報告深入探討了全球 EGFR 檢測市場，包括競爭格局、SWOT 分析、到 2033 年的市場預測、COVID-19 的影響、區域和國家趨勢等。Masu。

目錄

目前已上市的EGFR檢測及競爭狀況

• 對主要產業趨勢的見解
• 2015 年至 2033 年 EGFR 檢測按細分市場劃分的市場總收入和市場前景
• 有關數量、平均售價和市場價值的詳細數據

全球、區域與國家見解

• EGFR檢測市場的SWOT分析
• EGFR 檢測市場的競爭動態洞察與趨勢
• 各國醫療保健系統概覽
• 按國家/地區劃分的報銷政策
• 各國醫療科技的監管狀況

Abstract

EGFR Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on EGFR Tests market for the year 2020 and beyond. Globally, lung cancer is the second most common cancer in men and the third most common cancer in women. Secondary sources estimate that approximately 2.0 million new cases of lung cancer were reported worldwide in 2018. Cigarette smoking is the dominant risk factor associated with lung cancer across all age groups, with approximately 80% of male and 45% of female lung cancer cases worldwide attributed to smoking.

EGFR is a member of the receptor tyrosine kinase family and a major factor in regulating cellular proliferation, invasion, metastasis, angiogenesis, and inhibition of apoptosis. EGFR is one of the most routinely tested biomarker in NSCLC.

Most EGFR mutations found in adenocarcinoma are located in the tyrosine kinase domain. The most frequently encountered mutations are in-frame deletions in exon 19 (around 45%) and a point mutation in exon 21 (L858R), which together account for over 85% of described mutations. These mutations strongly correlate with NSCLC patients responding to EGFR therapies such as the tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib, afatinib, and icotinib.

The model includes EGFR Immunohistochemistry Tests, EGFR Sanger Sequencing Tests, EGFR Nucleic Acid Amplification Tests (NAATs), and EGFR Other Tests (EGFR ISH and Mass Array tests).

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed EGFR Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total EGFR Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for EGFR Tests market.
• Competitive dynamics insights and trends provided for EGFR Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: F. Hoffmann-La Roche Ltd, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, NimaGen BV, Mesa Laboratories Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, HLB PanaGene Co Ltd, and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the EGFR Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on EGFR Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving EGFR Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the EGFR Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific EGFR Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable